MaxCyte (NASDAQ:MXCT) is a life sciences company specializing in cell-engineering technologies that enable the development of advanced therapeutics and research applications. At the core of its offering is a proprietary Flow Electroporation platform, which allows for efficient, scalable and gentle delivery of macromolecules—such as nucleic acids, proteins and CRISPR/Cas9 components—into a wide range of cell types. The company’s instruments and reagent consumables are used by biotechnology and pharmaceutical companies for drug discovery, genome editing, cell therapy manufacturing and research workflows.
Its commercial product lines include the STX™ Scalable Transfection System for research and development applications, as well as the ATx™ and VLx™ platforms designed to meet the rigorous requirements of clinical and GMP-grade cell therapy production. In addition to instrument sales, MaxCyte offers transfection reagents and accessories that have been validated across multiple cell types. The company also partners with leading biopharmaceutical organizations to provide contract development and manufacturing services for cell therapy candidates advancing toward clinical trials.
Founded in 1998 and headquartered in Gaithersburg, Maryland, MaxCyte has established a global footprint with additional operations and support centers in Cambridge, United Kingdom, and offices that serve clients throughout North America, Europe and Asia. The company completed its initial public offering on the Nasdaq exchange under the ticker MXCT in 2016, marking a significant milestone in its transition from a technology provider to a commercial-stage life sciences enterprise.
Led by President and Chief Executive Officer Mark J. Cully, MaxCyte’s executive leadership team also includes Chief Financial Officer Trevor Clinger. Under their guidance, the company has formed strategic collaborations with major pharmaceutical and biotechnology firms and continues to expand its customer base, which encompasses both emerging biotech innovators and established global drug developers.
